Arcturus Therapeutics opened lower at $9.03, compared with its previous close of $9.31. In the last trading session, the stock traded between $8.42 and $9.07. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Arcturus Therapeutics is now worth
$ 22.54
Resulting in a loss of
$ 77.46 (77.46%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.87 (-9.38%)
Day High
$9.07
Day Low
$8.42
Day Open
$9.03
Prev Close
$9.31
Volume
3,34,900
1W Return
-22.33%
1M Return
-33.06%
3M Return
12.12%
6M Return
-2.29%
1Y Return
-2.69%
Market Cap ($ Mn)
243
PE Ratio
-
PB Ratio
2.51
PEG Ratio
-
ROE
-28.74%
ROCE
-28.98%
EPS (TTM)
$-0.26
1 Week
-22.33%
1 Month
-33.06%
3 Months
12.12%
6 Months
-2.29%
9 Months
14.01%
Arcturus Therapeutics Q3 Results: Net loss narrows to $7.4 million
Net loss narrowed to $7.4 million in Q3 from $13.4 million in the prior year. Revenue rose to $18.3 million, boosted by $12 million CSL Seqirus termination payment. Cash position stands at $184.8 million with runway extending through 2028. LUNAR 2.0 technology shows 38-fold potency improvement in preclinical models.
7 days agoArcturus regains global vaccine rights, holds $191.5 million cash
Arcturus regained global rights to Kostaive and its mRNA platform from CSL Seqirus. Cash position stands at $191.5 million with runway extending through year-end 2028. Phase 3 decision for CF candidate ARCT032 expected in Q4 2026. OTC deficiency program ARCT810 completed Phase 2 dosing; data readout set for Q3 2026.
29 days agoArcturus stock gains 6.5% on positive Phase 2 data for ARCT-810
Shares gained 6.54% to $14.17 on positive Phase 2 interim data. ARCT-810 maintained normal fasting ammonia levels in OTC deficiency patients. LUNAR 2.0 platform shows >30-fold higher protein expression vs LUNAR 1.0. myNEO acquisition expected to close in October to boost AI infrastructure. Company holds $191.5 million in cash as of June 30, 2026.
1mo agoArcturus Therapeutics to present at five healthcare investor conferences
Arcturus Therapeutics will attend five investor conferences in September 2026. Events include fireside chats at Wells Fargo, Citi, and Cantor Fitzgerald. The company will present at the H.C. Wainwright conference on September 15. Investor meetings are scheduled at the ROTH Healthcare Opportunities Conference. Webcast links will be posted on the Arcturus investor relations website.
2mo agoArcturus Therapeutics Q2 Results: Financials and update due Aug 6
Arcturus Therapeutics Holdings Inc. scheduled its Q2 2026 earnings release for Aug 6, 2026, after market close. The firm will host a concurrent conference call at 4:30 pm ET to discuss corporate updates. No financial metrics are provided in this notice, but the call may cover progress on its mRNA pipeline for rare diseases and pandemic vaccines.
3mo agoArcturus Therapeutics to present at Canaccord Genuity conference
Arcturus Therapeutics Holdings Inc. announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The fireside chat will be available via webcast on the company's website.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Arcturus Therapeutics is now worth
$ 22.54
Resulting in a loss of
$ 77.46 (77.46%)
Note: Past profits do not guarantee future returns.
